An investigational oral GLP-1 receptor agonist helped adults with overweight or obesity lose up to 11.3% more body weight than placebo over 36 weeks, according to a phase 2b study published July 1 in Nature Medicine. Here are four things…
GLP-1s
CMS is rolling out the Medicare GLP-1 Bridge program — a demonstration designed to give eligible Medicare Part D beneficiaries access to certain GLP-1s at a fixed monthly cost — July 1. CMS officials, including CMS Administrator Mehmet Oz, MD,…
The FDA has released the names of panel members who will weigh in on whether seven popular peptides should be more widely available for pharmacy compounding. The new roster mainly includes physicians who run wellness, longevity and regenerative medicine clinics…
Treatment with the GLP-1 receptor agonist semaglutide was associated with slower biological aging in adults with HIV-associated lipohypertrophy, according to a study published May 19 in Nature Communications. Here are four things to know:
GLP-1 receptor agonist use was associated with a higher risk of smell and taste disturbances among adults with Type 2 diabetes, according to a study published June 25 in JAMA Otolaryngology-Head & Neck Surgery. Here are four things to know…
Advertisement
The Institute for Safe Medication Practices has identified five recurring medication errors involving GLP-1 therapies as use of the medications continues to grow for diabetes and obesity treatment, according to a June 25 news release. The findings come as GLP-1…
Walgreens will begin supporting eligible Medicare beneficiaries through the new Medicare GLP-1 Bridge program at about 8,000 pharmacies when the initiative launches July 1. More than 56 million patients in the Medicare network may be eligible for the program, according…
CVS Health, Walmart and Sam’s Club announced they are expanding support for Medicare beneficiaries as the Medicare GLP-1 Bridge program prepares to launch July 1. Established under agreements the Trump administration negotiated with Eli Lilly and Novo Nordisk in November,…
A wave of new research is expanding what clinicians and health system leaders know about GLP-1 medications — covering new territory from liver disease to male fertility to a blood pressure safety signal. Here are eight recent findings:
GLP-1 medications did not harm male hormones or fertility after long-term use and may improve testosterone levels and sperm quality in men with obesity-related low testosterone, according to research being presented at the Endocrine Society’s annual meeting in Chicago. Here…